Niwinas (Desmopressin Acetate)

Desmopressin acetate, the active ingredient in Niwinas, is a vasopressin (antidiuretic hormone) analog presented as an oral tablet for oral use. It is employed to manage central diabetes insipidus, reduce nocturnal enuresis, and serve as a hemostatic agent in hemophilia A and von Willebrand disease for patients requiring controlled water balance or clotting support.

GNH USA supplies Niwinas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assurance processes and regulatory approvals across multiple continents.

Desmopressin acetate acts on the antidiuretic hormone pathway to regulate water balance and promote clotting factor release.

Central diabetes insipidus: reduces excessive urine output by enhancing renal water reabsorption. Nocturnal enuresis: decreases nighttime bedwetting episodes through concentrated urine formation. Hemophilia A: raises plasma factor VIII levels to improve clot formation. von Willebrand disease: increases von Willebrand factor concentration, aiding platelet adhesion and hemostasis.

Desmopressin acetate may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Headache - Nausea - Nasal congestion

Serious or Rare Side Effects: - Severe hyponatremia with seizures - Water intoxication - Allergic reactions (rash, angioedema)

When prescribing desmopressin acetate, clinicians should consider several safety measures.

Assess fluid balance before initiating therapy: evaluate patient hydration status. Monitor serum sodium regularly during treatment: detect early hyponatremia. Adjust dose in patients with renal impairment: reduced clearance may increase risk. Use caution in elderly patients prone to hyponatremia: lower doses may be needed. Avoid concomitant use with other antidiuretic agents: risk of excessive water retention. Store at below 25°C: keep in the original pack, protect from moisture.

Desmopressin acetate can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concomitant use with other V2‑receptor agonists: additive antidiuretic effect. - Co‑administration with thiazide diuretics: heightened risk of hyponatremia. - NSAIDs that reduce renal prostaglandins: may increase water retention.

Moderate Interactions (Monitor Closely): - Carbamazepine or phenytoin: increase desmopressin clearance, reducing efficacy. - CYP3A4 inducers such as rifampin: may lower plasma levels. - Antihypertensive agents: potential additive hypotensive effect.